In this episode we're joined by Dr Stefan Nilsson, founder and CEO of Lipigon Pharmaceuticals, where he discusses the challenges and opportunities in treating metabolic diseases such as dyslipidemia. We also go on to discuss how Lipigon operates as a virtual biotech, allowing it to remain nimble in its efforts to develop novel therapies against a wide range of diseases. Lipigon was founded in 2010 based on over 50 years of research in lipid biology at Umea University in Sweden. Lipigon...

Prof Chas Bountra, Pro-Vice Chancellor for Innovation and Professor of Translational Medicine at the University of Oxford, joins us in the second episode of Biotech Frontiers for a discussion on the Oxford innovation ecosystem, with a focus on public-private partnerships and initiatives, and the importance of collaboration. Chas draws on his vast experience across industry and academia to suggest ways in which we can better tackle some of the most challenging healthcare problems, such as anti...

Dr Steve Tregay, Managing General Partner of Mission BioCapital, and Chairman of Lab Central, joins the first episode of Biotech Frontiers for a discussion on how to build enduring, innovative biotech ventures. Drawing on his deep experience as a founder and investor, Steve considers the transformative power of innovation clusters, and the future of venture creation in biotech. Steve Tregay, PhD is a Managing General Partner of Mission BioCapital, based in their Cambridge office. He focuses ...